The HTA review remains shrouded in secrecy, with brief and vaguely worded agendas released after meetings are held, no communiqués published for the past seven meetings, and organisations in other countries knowing more about the options under consideration and seeming to have more input than the Australian community.
But for a few selected insiders, the HTA review is a 'bin fire' of non-transparency
September 11, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News -
Commercial outsourcing emerges as a strategic option to patient access
July 1, 2026 - - Latest News -
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - - Latest News -
Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - - Latest News


